COVID-19 clinical trials at UC Davis
6 research studies open to eligible people
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 18 years and up
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients
San Francisco, California and other locations
Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
open to eligible people ages 18 years and up
Immunocompromised individuals, such as solid organ transplant (SOT) recipients are at high risk of COVID-19 associated complications and mortality. Retrospective studies so far have shown that a majority of SOT recipients did not develop appreciable anti-spike antibody response after a first, second, or even third dose of mRNA vaccine. Treatment with antimetabolites was associated with poor vaccine response. The goal of this study is 1) examine whether transient immunosuppression reduction improves the immune response to a third dose of SARS-CoV-2 mRNA vaccine in kidney transplant recipients and 2) to assess the safety of immunosuppression reduction before and after third dose SARS-CoV-2 mRNA vaccination.
Sacramento, California
ACTIV-3: Therapeutics for Inpatients With COVID-19
open to eligible people ages 18 years and up
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC.
Sacramento, California and other locations
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
open to eligible people ages 18 years and up
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Davis, California and other locations
PET/CT Imaging in COVID-19 Patients
open to eligible people ages 18 years and up
This is a PET/CT study using the 18F-αvβ6-binding-peptide.The goal of this study is to evaluate this peptide in patients after infection with SARS CoV2.
Sacramento, California
DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to all eligible people
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Sacramento, California and other locations
Our lead scientists for COVID-19 research studies include Stuart Cohen, MD Aileen X Wang, MD Timothy Albertson, MD Julie L. Sutcliffe, Ph.D.